EGFR and cancer: Likewise, Li et al. targeted EGFR overexpression in various cancer cells with an anti-epidermal growth factor receptor-targeted 131I-labeled nanoparticle with a specific radioactivity of 370–690 MBq/mg for their EGFR targeted NPs and non-targeted NPs, resulting in a ~50–85% labeling efficiency [71] in comparison to the labeling efficiency in this study of 98% (Figure 3 and Figure 7).